Key points are not available for this paper at this time.
A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Participants were assigned to take either a lifestyle modification (LM), or LM +30 g/day brown milled flaxseed for 12 weeks. At the end of the study, body weight, liver enzymes, insulin resistance and hepatic fibrosis and steatosis decreased significantly in both groups (p< 0.05); however, this reduction was significantly greater in those who took flaxseed supplementation (p < 0.05). The significant mean differences were reached in hepatic markers between flaxseed and control group, respectively: ALT -11.12 compared with -3.7 U/L; P< 0.001, AST -8.29 compared with -4 U/L; p < 0.001, GGT -15.7 compared with -2.62 U/L; p < 0.001, fibrosis score -1.26 compared with -0.77 kPa; p = 0.013 and steatosis score -47 compared with -15.45 dB/m; p = 0.022. In conclusion, flaxseed supplementation plus lifestyle modification is more effective than lifestyle modification alone for NAFLD management.
Yari et al. (Thu,) studied this question.